↓ Skip to main content

Diretrizes de conduta e tratamento de síndromes febris periódicas associadas a febre familiar do Mediterrâneo

Overview of attention for article published in Revista Brasileira de Reumatologia, January 2016
Altmetric Badge


9 Dimensions

Readers on

10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Diretrizes de conduta e tratamento de síndromes febris periódicas associadas a febre familiar do Mediterrâneo
Published in
Revista Brasileira de Reumatologia, January 2016
DOI 10.1016/j.rbr.2015.08.006
Pubmed ID

Maria Teresa R.A. Terreri, Wanderley Marques Bernardo, Claudio Arnaldo Len, Clovis Artur Almeida da Silva, Cristina Medeiros Ribeiro de Magalhães, Silvana B. Sacchetti, Virgínia Paes Leme Ferriani, Daniela Gerent Petry Piotto, André de Souza Cavalcanti, Ana Júlia Pantoja de Moraes, Flavio Roberto Sztajnbok, Sheila Knupp Feitosa de Oliveira, Lucia Maria Arruda Campos, Marcia Bandeira, Flávia Patricia Sena Teixeira Santos, Claudia Saad Magalhães


To establish guidelines based on scientific evidence for the management of familial Mediterranean fever. The Guideline was prepared from 5 clinical questions that were structured through PICO (Patient, Intervention or indicator, Comparison and Outcome), to search in key primary scientific information databases. After defining the potential studies to support the recommendations, these were graduated considering their strength of evidence and grade of recommendation. 10,341 articles were retrieved and evaluated by title and abstract; from these, 46 articles were selected to support the recommendations. 1. The diagnosis of FMF is based on clinical manifestations, characterized by recurrent febrile episodes associated with abdominal pain, chest or arthritis of large joints; 2. FMF is a genetic disease presenting an autosomal recessive trait, caused by mutation in the MEFV gene; 3. Laboratory tests are not specific, demonstrating high serum levels of inflammatory proteins in the acute phase of the disease, but also often showing high levels even between attacks. SAA serum levels may be especially useful in monitoring the effectiveness of treatment; 4. The therapy of choice is colchicine; this drug has proven effectiveness in preventing acute inflammatory episodes and progression towards amyloidosis in adults; 5. Based on the available information, the use of biological drugs appears to be an alternative for patients with FMF who do not respond or are intolerant to therapy with colchicine.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 30%
Student > Bachelor 2 20%
Student > Postgraduate 2 20%
Student > Ph. D. Student 1 10%
Unknown 2 20%
Readers by discipline Count As %
Medicine and Dentistry 4 40%
Nursing and Health Professions 1 10%
Business, Management and Accounting 1 10%
Biochemistry, Genetics and Molecular Biology 1 10%
Unknown 3 30%